Topoisomerase II inhibitors carry significant risks of short-term and long-term toxicities, including cardiotoxicity, which necessitate careful monitoring and dose adjustments in vulnerable populations.
Supports cardiac monitoring with topoisomerase II inhibitors; leaves open prospective validation of dosing in organ dysfunction.
Topoisomerase II inhibitors represent a broad class of antineoplastic agents with a wide spectrum of activity against malignancies. Topoi-somerase II inhibitors include the anthracyclines, mitoxantrone and epipodophyllotoxins. Short-term toxicity includes myelosuppression and gastrointestinal toxicity. Long-term survivors are at risk of cardiac toxicity and secondary leukaemia. This article discusses these toxicities in detail, including administration of these agents to patients with hepatic and/or renal insuffi-ciency, and the need for dose adjustments in selected patient populations.
No takes yet. Share an insight, caveat, or question.
Karen Seiter (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: